TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00987714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocolized care
Description: Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
Study: NCT04218812

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: No electrical source imaging (ESI)
Description: For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No electrical source imaging (ESI)
Description: For all patients: MRI, semiology, visual interpretation of EEG, and in selected cases, PET, SPECT

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated electrical source imaging (ESI)
Description: The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Automated electrical source imaging (ESI)
Description: The automated source imaging consists of 2 phases~1. Automated detection of EDs~2. Source imaging of each spike cluster and seizure onset epoch.
Study: NCT01312519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OnControl Bone Marrow Biopsy and Aspiration System
Description: Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual bone marrow sampling device
Description: Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
Study: NCT01261364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GeneSightRx
Description: Multi-genetic pharmacogenomic panel

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual
Study: NCT04414540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Extended Release Oral Tablet
Description: Metformin ER starting dose 1000mg daily Metformin ER escalation dose 2000mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab q 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab q 3 weeks
Study: NCT03950258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endovascular embolization
Description: Transarterial embolization is done for patients with arteriovenous shunts as via transfemoral access using flow-guided microcatheter and an embolic agent is injected.
Study: NCT04265339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Description: Participants are required to quit smoking
Study: NCT01867944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perineal Self-Acupressure
Description: The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control
Description: Education on conventional treatment options for chronic constipation.
Study: NCT02288390

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care in mechanically ventilated patients
Description: Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral care in mechanically ventilated patients
Description: Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
Study: NCT03174951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIg
Description: Patients will take 400mg/kg IVIg at the time of positive pregnancy,Following the first administration, IVIG well given every 4 weeks through 32 weeks of gestation.
Study: NCT01284296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine digital block
Description: One dose of lidocaine 2% injected locally into one finger (2 mls total)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo SpHb continuous hemoglobin monitor
Description: Masimo SpHb continuous hemoglobin monitor
Study: NCT00446836

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel polyglumex (Xyotax)
Description: biologically enhanced chemotherapeutic
Study: NCT00418821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Laronidase
Description: dose of 0.58mg/kg body weight intravenously (IV) every week
Study: NCT00968292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prosthetics foot (K3 Promoter)
Description: The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental prosthetics foot (K3 Promoter)
Description: The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
Study: NCT04213976

Intervention type: PROCEDURE
Intervention: Ileostomy
Description: Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.

Intervention type: PROCEDURE
Intervention: Ileostomy
Description: Use of an ileostomy to decompress the proximal bowel, perfored either as a conventional loop ileostomy or as described by Santulli et al. or by Bishop and Koop.
Study: NCT03785392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 In-plane
Description: Group 1: Study will involve total of 15 patients with the procedure done in-plane. Before the block placement and after the block placement lung function will be measured.~FEV1 (forced expiratory volume in 1 second ) and FVC ( forced vital Capacity ) values will be recorded. Block will be performed in plane and postprocedure lung function test will be repeated. New values of FEV1 and FVC will be obtained after the placement of the nerve block.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 out of plane
Description: Group 2 study will adopt the out of plane technique and will involve a total of 15 patients in this group. We will do the procedure out of plane and will have lung function FEV1 and FVC measured bedside.FEV1 and FVC values will be recorded. Block will be performed out of plane and postprocedure lung function test will be measured. New values of FEV1 and FVC will be obtained
Study: NCT03346486

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control diet
Description: Regular diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention diet
Description: Brainfood dietary regime planned to be optimal for metabolism and cognitive function; having focus on regular meal frequency (breakfast, lunch and afternoon snack) and well-balanced light lunch at work according to the so-called plate model and optimized recipes- will be provided.
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
Study: NCT01495325

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
Study: NCT02027415

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 2 cups of orange juice will be given before the car ride

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: 2 cups of orange juice will be given before the car ride
Study: NCT04014270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-modulated functional electrical stimulation (SM-FES)
Description: The patient actively self-administers the electrical stimulation on the impaired limb by controlling the electrical stimulation device with the non-impaired hand. A device called the Intento PRO will be used to deliver the experimental treatment.~Duration: 90 min per day, 5 days per week, for 2 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The patient performs intensive, goal-oriented, repetitive functional exercises.~Duration: 90 min per day, 5 days per week, for 2 weeks.
Study: NCT04097015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-Stim M
Description: Alpha-Stim M with and Ocular Interface and a Spinal Interface
Study: NCT03226561

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phaco / Panoptix
Description: Phacoemulsification with bilateral diffractive trifocal lens implantation
Study: NCT03443609

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: 68Ga-HBED-CC-PSMA PET / CT
Description: Patient will receive a specific PET / CT with PSMA
Study: NCT03428451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 3% HS
Description: Hypertonic saline 3% is a type of crystalloid solution with osmolarity higher than that of plasma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 3% HS
Description: Hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 0.9% NS
Description: Normal saline 0.9% is a type of crystalloid solution with osmolarity similar to that of plasma.
Study: NCT01042951

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ShanChol Cholera Vaccine
Description: 55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
Study: NCT01495325

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Badimon Chamber
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study: NCT01985334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABA
Description: Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABA
Description: Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
Study: NCT01042951

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
Study: NCT04354779

Intervention type: DIAGNOSTIC_TEST
Intervention: a specifically designed self-administered questionnaire
Description: The questionnaire consists of the following items: questions related to personal health, traveling activities, living situation, as well as inquiries of symptoms and comorbidities.
Study: NCT00886418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: muscle relaxant
Description: muscle relaxant administration throughout anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
Study: NCT02562183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kallikrein
Description: Using kallikrein
Study: NCT04496557

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROCESS-INSTRUCTED SELF NEURO-MODULATION (PRISM)
Description: Neurofeedback sessions targeting down-regulation of deep limbic structures, specifically the amygdala, delievered via PRISM: a non-significant risk device (software) intended to be used in research studies testing the clinical efficacy of an innovative paradigm for EEG-based neurofeedback.~The study will include 12 EEG-NF sessions, administered twice per week for a duration of 6 active weeks in total. Twice weekly sessions will be held on non-consecutive days. Each session will last 30 minutes.~EFP-EEG-NF training: Each NF training session consists of 5 consecutive sequences of NF presentations. During a watch condition (60 seconds) participants are instructed to passively view the animation, and are told that that the scenario does not influence their brain activity. In the regulate phase (60 seconds) participants are instructed to lower the room's unrest level. A rest phase (15 seconds) follows each sequence, allowing participants to relax.
Study: NCT05278286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crawling stimulation with the crawliskate
Description: Consists of 2 months of daily training. Infants benefit from a 5 minutes session everyday at home with a trained therapist. During each session the infant is prone wrapped on the crawliskate and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tummy time without the crawliskate
Description: Consists of 2 months of daily training. Infants benefit from a 5-minutes session everyday at home with a trained therapist. During each session the infant is prone directly ona mattress and cannot benefit from any assistance from the therapist to move forward.
Study: NCT01343017

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilatory pattern
Description: In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.

Intervention type: OTHER
Group type: OTHER
Intervention: Ventilatory pattern
Description: In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
Study: NCT02016469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: co-transplantation of FMT and pectin
Description: 300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: single fecal microbiota transplantation
Description: single fecal microbiota transplantation once the first day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pure give pectin 20g/d for five days
Description: pure give pectin 20g/d for five days
Study: NCT01779648

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DVT-3000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCD Express
Study: NCT06182540

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango puree
Description: Mango puree 300g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mango puree
Description: Mango puree 300g
Study: NCT01867567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal bandage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal bandage
Study: NCT02861053

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: regular and moderate physical activity
Description: regular and moderate physical activity will be done 3 times per week more than usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular and moderate physical activity
Description: regular and moderate physical activity will be done 3 times per week more than usual

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No regular and moderate physical activity more than usual
Description: regular and moderate physical activity will be done as usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No regular and moderate physical activity more than usual
Description: regular and moderate physical activity will be done as usual
Study: NCT02800720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training
Description: 8 Week Meditation Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Groups
Description: 8 week intervention based on Cognitive Behavioral Theory
Study: NCT03979846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Application
Description: Use computer-based symptom reporting system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Application
Description: Use computer-based symptom reporting system

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04254432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic conditioning
Description: RIC is a physical strategy performed by an electric auto-control device with cuffs placed on unilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures are performed repeatedly for 5 times# two times per day. The duration of the treatment is 4 weeks.
Study: NCT03594253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regulation Focused Psychotherapy for Children
Description: RFP-C is a manualized, psychodynamic psychotherapy that last 10 weeks. Children meet individually with a therapist for play therapy (twice a week for 16 sessions) and parents meet with the therapist for four full sessions (without the child).
Study: NCT02137837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Anastrozole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - Anastrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Everolimus
Study: NCT03210220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pecs II block
Description: After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.